DR. STUART YOUNG, M.D.
Radiology at Las Piedras St, Menlo Park, CA
License number
California C37626
Category
Radiology
Type
Diagnostic Radiology
Address
Address
45 Las Piedras St, Menlo Park, CA 94028
Phone
(650) 207-1987
Personal information
See more information about STUART YOUNG at radaris.comName
Address
Phone
5334 Terrace Oak Cir, Fair Oaks, CA 95628
5746 Newcomb Ct, Fontana, CA 92336
4217 Merced Cir, Antioch, CA 94531
45 Las Piedras St, Portola Vally, CA 94028
47063 Kasbah Dr, Palm Desert, CA 92260
Professional information
Use Of Texaphyrins In Detection Of Melanin And Melanin Metabolites Diagnostic Of Melanotic Melanoma
US Patent:
6022526, Feb 8, 2000
Filed:
Jul 30, 1997
Appl. No.:
8/903099
Inventors:
Kathryn W. Woodburn - Sunnyvale CA
Stuart W. Young - Portola Valley CA
Stuart W. Young - Portola Valley CA
Assignee:
Pharmacyclics, Inc. - Sunnyvale CA
International Classification:
A61K 4900
US Classification:
424 961
Abstract:
Melanotic melanoma tumor or cells, melanin, or melanin metabolites are detected, identified, and localized when bound to texaphyrins or texaphyrin metal complexes. The present invention provides texaphyrins and texaphyrin metal complexes as reagents for in vivo or in vitro detection for melanin or melanin metabolites predictive of the presence of melanotic melanoma.
Dr. Stuart W Young, Portola Valley CA - MD (Doctor of Medicine)
Specialties:
Diagnostic Radiology
Address:
45 Las Piedras St, Portola Valley 94028
Certifications:
Diagnostic Radiology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Indiana University / School of Medicine
Graduated: 1969
Ny Hosp-Cornell Med Ctr
Harvard-Affil Hosps
Peter Bent Brigham
Indiana University / School of Medicine
Graduated: 1969
Ny Hosp-Cornell Med Ctr
Harvard-Affil Hosps
Peter Bent Brigham
Medical Devices And Materials Having Enhanced Magnetic Images Visibility
US Patent:
5817017, Oct 6, 1998
Filed:
May 24, 1995
Appl. No.:
8/446652
Inventors:
Stuart W. Young - Portola Valley CA
Richard A. Miller - Portola Valley CA
Richard A. Miller - Portola Valley CA
Assignee:
Pharmacyclics, Inc. - Sunnyvale CA
International Classification:
A61B 05055
US Classification:
600433
Abstract:
Catheters and other medical devices include a non-metallic member having paramagnetic ionic particles fixedly incorporated therethrough in order to provide enhanced detectability when viewed by magnetic imaging regardless of the orientation of the non-metallic member in the magnetic field. Catheters are usually formed from polymeric tubing, and the paramagnetic ionic particles are usually formed from paramagnetic ions incorporated with water or other proton-donating fluid into carrier particles, such as zeolites, molecular sieves, clays, synthetic ion exchange resins, and microcapsules. Catheters and other medical devices include a non-metallic member having small iron and/or superparamagnetic particles fixedly incorporated therethrough or thereover in order to provide enhanced detectability when viewed by magnetic imaging. Catheters are usually formed from polymeric tubing, and the iron and/or superparamagnetic particles at or near the surface of the catheter interact with the water protons of the surrounding patient's body to provide image enhancement regardless of the orientation of the polymeric or other non-metallic material in the magnetic field.
Methods For Cancer Chemosensitization
US Patent:
5776925, Jul 7, 1998
Filed:
Jan 25, 1996
Appl. No.:
8/591318
Inventors:
Stuart W. Young - Portola Valley CA
Richard A. Miller - Portola Valley CA
Richard A. Miller - Portola Valley CA
Assignee:
Pharmacyclics, Inc. - Sunnyvale CA
International Classification:
A61K 3140
US Classification:
514185
Abstract:
Methods for cancer chemosensitization are provided. Texaphyrins are new chemosensitizers for enhancing the cytotoxicity of chemotherapeutic agents. The enhancement appears to be P-glycoprotein-independent since texaphyrins are effective in both a P-glycoprotein-expressing and a P-glycoprotein -nonexpressing cell line. Methods are provided for the treatment of cancers such as leukemia, lymphoma, carcinoma, and sarcoma using a texaphyrin as a chemosensitizer.
Gene Delivery Formulations And Methods For Treatment Of Ischemic Conditions
US Patent:
2009020, Aug 20, 2009
Filed:
May 2, 2008
Appl. No.:
12/114330
Inventors:
Michael E. Coleman - Hauts-de-Seine, FR
Fiona MacLaughlin - Belfast, IE
Jijun Wang - Pearland TX, US
Mary L. Thiesse - Houston TX, US
Stuart Young - Portola Valley CA, US
Jeffrey Nordstrom - College Station TX, US
Fiona MacLaughlin - Belfast, IE
Jijun Wang - Pearland TX, US
Mary L. Thiesse - Houston TX, US
Stuart Young - Portola Valley CA, US
Jeffrey Nordstrom - College Station TX, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 31/713, C12N 5/00, A61P 9/10, A61K 31/711
US Classification:
514 44 R, 435375, 514 12, 424 932
Abstract:
The present inventors have developed a novel approach for efficient delivery of angiogenic factors to the cardiac and peripheral vasculature that avoids problems with toxicity inherent to existing delivery technologies. Vectors carrying coding sequences for angiogenic agents including Del-1 or VEGF, or both, can be formulated with poloxamers or other polymers for delivery into ischemic tissue and delivered to areas of peripheral ischemia in a flow to no-flow pattern and to the heart by retrograde venous perfusion.
Use Of Texaphyrin In Ocular Diagnosis And Therapy
US Patent:
2002002, Feb 28, 2002
Filed:
Aug 2, 2001
Appl. No.:
09/922350
Inventors:
Mark Blumenkranz - Portola Valley CA, US
Kathryn Woodburn - Sunnyvale CA, US
Richard Miller - Portola Valley CA, US
Stuart Young - Portola Valley CA, US
Kathryn Woodburn - Sunnyvale CA, US
Richard Miller - Portola Valley CA, US
Stuart Young - Portola Valley CA, US
Assignee:
Pharmacyclics, Inc.
International Classification:
A61K049/00, A61K031/555, A61K031/407
US Classification:
424/009600, 514/185000, 514/410000, 604/020000
Abstract:
The use of texaphyrins for ocular diagnosis and therapy is provided, especially use of photosensitive texaphyrins for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, or pterygium, for example. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the photosensitive texaphyrin is metallated with lutetium. Due to the dual wavelength absorption of texaphyrins, i.e., at 400-500 nm and at 700-800 nm, especially about 732 nm, as compared to porphyrins, texaphyrins are more effective and versatile for use in humans as compared to porphyrins. Texaphyrins serve as effective contrast agents in ocular angiography.
Use Of Texaphyrins In Macrophage-Mediated Disease
US Patent:
2002011, Aug 22, 2002
Filed:
Jan 5, 2001
Appl. No.:
09/755795
Inventors:
Kathryn Woodburn - Sunnyvale CA, US
Stuart Young - Portola Valley CA, US
Stuart Young - Portola Valley CA, US
Assignee:
Pharmacyclics, Inc.
International Classification:
A61B005/055, A61K031/555, A61K031/409
US Classification:
514/185000, 514/410000, 604/020000
Abstract:
The present invention provides methods for treating disease of a subject in need thereof by sensitizing the effects of a co-therapeutic agent in macrophages. The method comprises administering a texaphyrin and a co-therapeutic agent to the subject. Texaphyrins are provided for enhancing the cytotoxicity of therapeutic agents in macrophage-mediated disease since texaphyrins have been shown to accumulate in macrophage.
Use Of Texaphyrin In Ocular Diagnosis And Therapy
US Patent:
6270749, Aug 7, 2001
Filed:
Jun 10, 1999
Appl. No.:
9/329720
Inventors:
Mark S. Blumenkranz - Portola Valley CA
Kathryn W. Woodburn - Sunnyvale CA
Richard A. Miller - Portola Valley CA
Stuart W. Young - Portola Valley CA
Kathryn W. Woodburn - Sunnyvale CA
Richard A. Miller - Portola Valley CA
Stuart W. Young - Portola Valley CA
Assignee:
Pharmacyclics, Inc. - Sunnyvale CA
International Classification:
A61K 4900, A01N 5502
US Classification:
424 961
Abstract:
The use of texaphyrins for ocular diagnosis and therapy is provided, especially use of photosensitive texaphyrins for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, or pterygium, for example. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the photosensitive texaphyrin is metallated with lutetium. Due to the dual wavelength absorption of texaphyrins, i. e. , at 400-500 nm and at 700-800 nm, especially about 732 nm, as compared to porphyrins, texaphyrins are more effective and versatile for use in humans as compared to porphyrins. Texaphyrins serve as effective contrast agents in ocular angiography.
Gene Delivery Formulations And Methods For Treatment Of Ischemic Conditions
US Patent:
2004000, Jan 15, 2004
Filed:
Apr 18, 2003
Appl. No.:
10/419045
Inventors:
Michael Coleman - Hauts-de-Seine, FR
Fiona MacLaughlin - Northern Ireland, GB
Jijun Wang - Pearland TX, US
Mary Thiesse - Houston TX, US
Stuart Young - Portola Valley CA, US
Jeffrey Nordstrom - College Station TX, US
Fiona MacLaughlin - Northern Ireland, GB
Jijun Wang - Pearland TX, US
Mary Thiesse - Houston TX, US
Stuart Young - Portola Valley CA, US
Jeffrey Nordstrom - College Station TX, US
International Classification:
A61K048/00, A61K009/14
US Classification:
514/044000, 424/486000
Abstract:
The present inventors have developed a novel approach for efficient delivery of angiogenic factors to the cardiac and peripheral vasculature that avoids problems with toxicity inherent to existing delivery technologies. Vectors carrying coding sequences for angiogenic agents including Del-1 or VEGF, or both, can be formulated with poloxamers or other polymers for delivery into ischemic tissue and delivered to areas of peripheral ischemia in a flow to no-flow pattern and to the heart by retrograde venous perfusion.
Photodynamic Therapy Of Pigment-Related Lesions
US Patent:
5775339, Jul 7, 1998
Filed:
Aug 19, 1997
Appl. No.:
8/914272
Inventors:
Kathryn W. Woodburn - Sunnyvale CA
Qing Fan - Sunnyvale CA
Stuart W. Young - Portola Valley CA
Qing Fan - Sunnyvale CA
Stuart W. Young - Portola Valley CA
Assignee:
Pharmacyclics, Inc. - Sunnyvale CA
International Classification:
A61B 1900
US Classification:
128898
Abstract:
The present invention involves the use of a photosensitive texaphyrin for the photodynamic treatment of a pigmented lesion, such as a melanodermic lesion, or a lesion obscured by pigmented tissue such as melaniferous tissue in a subject. In particular, the invention provides a treatment for the metastatic process of melanoma, and a method for inhibiting growth of established metastases of melanoma. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the texaphyrin is metallated with lutetium. Heretofore, melanoma has been refractory to treatment with photodynamic therapy.